Evidence map›Paper›PMID 42613019›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

Containment of a Candidozyma auris Outbreak in an Acute Care Hospital using a Comprehensive Screening and Surveillance Program.

Chloe Bryson-Cahn, Emily W Helm, Vanessa A Makarewicz, Eli A Piliper, Shah A Mohamed Bakhash, Maddi Danks, Bonnie MacLeod, Raquel Dixon, Leigh Haldeman, Yashika Harris and 6 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Chloe Bryson-CahnDivision of Allergy & Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.ORCID 0000-0003-0246-4012
Emily W HelmDepartment of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA.ORCID 0000-0003-1684-1560
Vanessa A MakarewiczInfection Prevention & Control, Harborview Medical Center, Seattle, WA, USA.
Eli A PiliperDepartment of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA.ORCID 0009-0005-9278-3907
Shah A Mohamed BakhashDepartment of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA.
Maddi DanksInfection Prevention & Control, Harborview Medical Center, Seattle, WA, USA.
Bonnie MacLeodInfection Prevention & Control, Harborview Medical Center, Seattle, WA, USA.
Raquel DixonInfection Prevention & Control, Harborview Medical Center, Seattle, WA, USA.
Leigh HaldemanInfection Prevention & Control, Harborview Medical Center, Seattle, WA, USA.
Yashika HarrisInfection Prevention & Control, Harborview Medical Center, Seattle, WA, USA.
Monica HoefsmitInfection Prevention & Control, Harborview Medical Center, Seattle, WA, USA.
Nathanael NapolitanoInfection Prevention & Control, Harborview Medical Center, Seattle, WA, USA.ORCID 0009-0007-6354-9948
Krista RietbergInfection Prevention & Control, Harborview Medical Center, Seattle, WA, USA.ORCID 0000-0002-9165-6157
Lori BourassaDepartment of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA.ORCID 0000-0001-8903-5274
John B LynchInfection Prevention & Control, Harborview Medical Center, Seattle, WA, USA.ORCID 0000-0001-9018-8542
Alexander L GreningerDepartment of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA.

Funding

Reproductive and Child Health StaRR ProgramR38AI181011 · NIAID · UNIVERSITY OF WASHINGTON · PI Kristina M. Adams Waldorf · 2025 to 2026
$805k
NIAID NIH HHS R38 AI181011
6 · The paper itself

Abstract

backgroundCandidozyma auris (C. auris) causes prolonged asymptomatic colonization and widespread silent healthcare transmission. An unknown proportion of patients who are colonized will progress to invasive candidiasis. Although culture has been the traditional method of colonization detection, PCR-based assays are now increasingly used for diagnosis and for evaluation of healthcare outbreaks.

methodsDuring a six-month, multi-hospital unit C. auris outbreak in a 500-bed urban public hospital, screening transitioned from chromogenic culture to open-access low-throughput PCR and house-wide high-throughput PCR, mandated via electronic admission order sets. Infection prevention and control interventions included electronic health record contact tracing, "Contact Plus" precautions, double-bleach cleaning, dual UV-C disinfection, and ATP environmental monitoring. Whole genome sequencing evaluated clonality.

resultsAdmission screening was performed for all newly admitted patients and weekly surveillance testing for all inpatients during the outbreak, with testing scaled from 1,181 cultures to 1,539 low-throughput PCRs and 8,918 high-throughput PCRs, reducing median turnaround times from 82.1 to 37.6 and 20.3 hours, respectively. Twenty-nine colonized patients were identified, with 50% of secondary cases linked to bed spaces previously occupied by colonized individuals. Sequencing confirmed a highly clonal Clade I cluster. Transmission was halted only after introducing universal PCR screening alongside enhanced infection prevention and control interventions. Notably, no patients experienced symptomatic infection with C. auris or required antifungal therapy.

conclusionsHigh-throughput, rapid PCR screening combined with rigorous infection prevention and control practices can successfully contain healthcare-associated C. auris outbreaks. Transitioning laboratory-developed tests to open-access, high-throughput platforms significantly enhances hospital outbreak response capacity.

Indexed as

Candida aurisCandidozyma aurishospital-acquired outbreaklaboratory developed testopen access platform

Identifiers

PMID42613019
PMCPMC13659896

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.